Avidity Biosciences, Inc.
Clinical trials sponsored by Avidity Biosciences, Inc., explained in plain language.
A biopharmaceutical company developing antibody-oligonucleotide conjugates.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a targeted infusion slow muscle decline in duchenne? a new trial aims to find out. Results expected Apr 2027 (estimated)
-
New hope for DM1: Long-Term trial of AOC 1001 underway
Disease control By invitation onlyThis phase 3 study is testing the long-term safety and effectiveness of an experimental drug called AOC 1001 (del-desiran) for people with myotonic dystrophy type 1 (DM1), a genetic muscle disorder. The trial enrolls 230 adults who have completed a prior AOC 1001 study and will r…
Phase 3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a targeted infusion slow muscle decline in duchenne? a new trial aims to find out.
Disease control OngoingThis phase 2 trial tests an experimental drug called AOC 1044 in people with Duchenne muscular dystrophy whose genetic mutation makes them candidates for exon 44 skipping therapy. The drug is given by intravenous infusion. Researchers are evaluating long-term safety and whether i…
Phase 2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New hope for FSHD: Long-Term drug safety trial underway
Disease control OngoingThis study is for people with FSHD, a genetic disease that causes muscle weakness. It tests the long-term safety and how well the body tolerates a drug called AOC 1020, given through a vein. About 84 adults who completed a previous study will take part. The main goal is to check …
Phase 2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC